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Conformational analysis of the mannosidase inhibitor 
kifunensine: a quantum mechanical and structural approach 
Alexandra Males,1,Á Lluís Raich,2,Á Spencer J Williams3 Carme Rovira2,4,* and Gideon J Davies1,* 
Abstract: The varied yet family-specific conformational pathways 
utilized by individual glycoside hydrolases (GHs) offer a tantalising 
prospect for the design of tight binding and specific enzyme 
inhibitors. A cardinal example of a GH family specific inhibitor, and 
one that finds widespread practical use, is the natural product 
kifunensine, which is a low nanomolar inhibitor selective for GH 
family 47 inverting D-mannosidases. Here we show, through 
quantum mechanical approaches, that kifunensine is restrained to a 
'ring-flipped' 1C4 conformation with another accessible, but higher-
energy, region around the 1,4B conformation. The conformations of 
kifunensine in complex with a range of GH47 enzymes including an 
atomic level (1 Å) resolution structure of kifunensine with 
Caulobacter sp. CkGH47 reported herein, and on GH family 38 and 
92 D-mannosidases, were mapped onto the kifunensine free energy 
landscape. These studies revealed that kifunensine has the ability to 
mimic the product state of GH47 enzymes but cannot mimic any 
conformational states relevant to the reaction coordinate of 
mannosidases from other families. 
There is compelling evidence that the enzymatic hydrolysis of 
glycosides, catalyzed by glycoside hydrolases (GHs) or 
glycosidases, occurs via a transition-state(s) with significant 
oxocarbenium ion character. For pyranoside-active enzymes, 
Sinnott was the first to argue that the allowed canonical 
conformations of the transition state sugar ring were two half-
chairs (4H3 and 3H4; and their closely related envelope 
conformations) and two boats (2,5B and B2,5).[1] Sustained efforts 
to map the conformational reaction pathways of glycosidases 
leading from substrate to product via the transition state(s) have 
revealed that individual glycosidases are optimized to act on 
substrates and follow a defined conformational itinerary through 
a specific transition-state conformation.[2] Glycosidases that are 
sequence related (for family classification see www.cazy.org; 
www.cazypedia.org)[3] and act on sugars with the same 
configuration are believed to act with identical conformational 
reaction itineraries. It is also apparent that GHs from different 
families that act on substrates with the same stereochemical 
configuration can utilize different conformational itineraries 
during catalysis. Given that mimicry of the enzymatic transition-
state is a powerful approach to inhibitor design and enzyme 
inhibition,[4] the potential exists for molecules to be designed or 
discovered with intrinsically-biased conformations that could act 
as GH family-specific enzyme inhibitors. However, to achieve 
specificity inhibitor design might not be limited to transition state 
mimicry but could target any distinctive conformational state 
along the reaction coordinate. However, while highly appealing, 
efforts to design molecular scaffolds that predispose inhibitors to 
conformations matching that of the transition state of a specific 
GH have been disappointing. For example, molecular 
constraints that restrict conformational mobility typically result in 
steric clashes that prevent efficient binding.[5] As well, a recent 
study that identified a unique stereoelectronic bias of 
mannopyranosiduronic iminosugars failed to deliver effective 
inhibition of a conformationally-matched D-mannosidase, 
presumably because of the inability to accommodate the 
requisite carboxylate group.[6] In the context of the failure thus 
far of rational design methods to achieve conformationally-
specific inhibition, one compound from nature, kifunensine 1, 
stands prominent as a powerful and family-specific enzyme 
inhibitor. Kifunensine 1 (Scheme 1) is an unusual oxalamide-
fused iminosugar with high specificity for D-mannosidases of GH 
family 47.  
 
Scheme 1. Assorted mannosidase inhibitors. 
Kifunensine is produced by the actinobacterium 
Kitasatosporia kifunense strain No. 9482.[7] Originally isolated on 
the basis of immunomodulatory properties, it was soon identified 
as a potent inhibitor of selected D-mannosidases.[8] The major 
contemporary applications of kifunensine stem from its activity 
as a specific inhibitor of class I GH47 D-mannosidases involved 
in glycoprotein biosynthesis within the secretory pathway that 
that are specific for the hydrolysis of Į-1,2-glycosidic bonds.[9] 
During glycoprotein biosynthesis, glucosylated high mannose N-
glycans are appended to nascent unfolded peptide chains in the 
endoplasmic reticulum (ER), whereupon they undergo a range 
of trimming reactions in the ER that assist in the unfolded 
peptide achieving the folded state, and subsequent trimming 
reactions in the Golgi apparatus that remove additional mannose 
residues prior to late stage glycosylation reactions.[10] As part of 
this process, a quality control mechanism termed ER associated 
degradation (ERAD) extracts terminally-misfolded proteins from 
the secretory pathway for proteosomal degradation.[11] 
Kifunensine-sensitive D-mannosidases are found within both the 
normal trimming pathway (ER mannosidase I, Golgi 
mannosidase I), and within the ERAD pathway (ER degradation-
enhancing mannosidase-like proteins 1, 2 and 3).[12]  
 The powerful and specific inhibition of GH47 D-
mannosidases by kifunensine has led to its widespread use for 
manipulation of N-glycan structure. In the structural biology 
context it is used to improve the homogeneity and crystallization 
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of proteins by arresting glycan remodeling to yield high mannose 
glycans that are more easily cleaved by endoH.[13] Kifunensine is 
also used in the production of therapeutic proteins. The 
effectiveness of acid E-glucocerebrosidase as a treatment for the 
lysosomal storage disorder Gaucher's disease depends upon 
the presence of high mannose N-glycans of this protein, which 
enable ligation to mannose receptors and delivery to 
lysosomes.[14] The lysosomal replacement therapy protein 
Velaglucerase alfa (acid E-glucocerebrosidase) is produced by 
Shire Plc by culturing HT1080 fibrosarcoma cells expressing 
acid E-glucocerebrosidase in the presence of kifunensine²this 
promotes the biosynthesis of enzyme decorated by immature 
high mannose-type N-linked glycan chains.[15] 
 Structural studies on GH47 enzymes, firstly the seminal 
work by the Howell group on the human ER ManB1 D-1,2-
mannosidase,[16] and subsequent work on a Penicillium citrinum 
homolog[12c] revealed kifunensine to bind in a 'ring-flipped' 1C4 
conformation. This conformation is unusual for an iminosugar; 
relative to the proposed conformational pathway, 3S1 o [3H4]Á o 
1C4 (Scheme 2),[2b, 16-17] for this family of enzymes it provides 
conformational mimicry of the product. Of relevance to this 
observation, a complex of noeuromycin 2 bound to a bacterial D-
mannosidase of family GH47, Caulobacter sp. K31 (CkGH47) 
also adopted a 1C4 conformation, which on the basis of 
computational work was assigned as a product-mimicking 
species.[17a] However, in the case of noeuromycin, the 
computational analysis of the inhibitor reveals that it favours a 
4C1 conformation,[18] and the observed conformation on-enzyme 
would therefore appear to be as a consequence of the enzyme 
restricting its shape to a higher energy conformation. Because of 
the widespread application of kifunensine, and its unique 
specificity as a GH47 selective D-mannosidase inhibitor, we 
sought to understand its specificity by developing a quantitative 
view of the conformational preferences of this compound when 
isolated, relative to bound states on D-mannosidases from GH 
family 47 and other families.  
 
Scheme 2. Conformational itineraries for inverting D-mannosidases 
proceeding through (left) OS2 o [B2,5]Á o 1S5 (e.g. GH family 125) and (right) 
3S1 o [3H4]Á o 1C4 (GH family 47) pathways. 
 Structures are available for kifunensine bound to Homo 
sapiens[16] and P. citrinum[12c] family 47 D-mannosidases at 
medium resolutions of 1.75 Å and 2.20 Å, respectively. In order 
to allow comparison to conformations that the ɲ-mannoside 
substrate follows during catalysis, we sought to obtain a higher 
resolution structure on CkGH47 D-mannosidase, which we have 
previously shown to provide atomic resolution diffraction data 
(Table 1). Kifunensine, shown here using isothermal titration 
calorimetry, is a tight binding (KD = 39 nM) inhibitor of CkGH47 
(Figure 1a). Crystals of a complex of CkGH47 bound to 
kifunensine diffracted to 1.05 Å resolution (Figure 1b). 
Kifunensine binds to CkGH47 in a 1C4 conformation, in line with 
the conformation observed in the structures with the H. sapiens 
and P. citrinum GH47 D-mannosidases. 
 
Table 1. Data and structure quality for 1 in complex with CkGH47 (PDB code 
5NE5).  
Resolution (Å) 72-1.05  
Rmerge 0.090 (0.88) 
CC(1/2) 1.00 (0.53) 
Completeness (%) 99.2 (99.6) 
Rwork / Rfree 0.12/0.14 
rmsdbonds (Å) 0.020 
 
Conformational free energy landscapes (FELs) are 
quantitative maps of the energy of the full suite of conformations 
of a molecule, and provide insight into locally and globally stable 
conformations and the barriers that must be crossed in order to 
achieve them. In order to understand the conformational 
landscape of kifunensine, and how this contributes to its GH47 
specific inhibition, its conformational FEL was calculated by ab 
initio metadynamics[19] using methods we have developed and 
applied to a range of glycosidase inhibitors.[18, 20] The kifunensine 
FEL (Figure 2, top) exhibits a strong preference for the µsouthern 
hemisphere¶ 1C4 conformation, which is consistent with the 
conformation observed in a small molecule, single crystal X-ray 
structure.[8, 21] A low energy zone is also seen around the 
1S3/1,4B/1S5 region of the FEL, which at approximately 7-8 
kcal/mol higher in energy, and with a minimal barrier, can be 
considered energetically accessible. Overall, the isolated 
kifunensine FEL can be considered strongly constrained to a 
ring-flipped 1C4 conformation, with limited ability to adopt a small 
set of 'equatorial' conformations.  Plotting the conformations of 
kifunensine observed in representative GH47 crystal structures 
(for enzymes from H. sapiens and B. thetaitaomicron), onto the 
isolated kifunensine FEL reveals that they lie close together in 
the low energy zone, with similar conformations to that of the 
small molecule, single crystal X-ray structure, suggesting that 
little distortion occurs upon binding to GH47 enzymes (the 
apparent differences reflect distortion near the poles of a 
Mercator projection (for a Polar projection and direct comparison, 
see SI Figure S1). Confluent with the FEL for 1, an FEL 
calculated for methyl D-mannoside within the active-centre 
environment of the CkGH47 (Figure 2, bottom) revealed that this 
molecule is heavily distorted away from its preferred 4C1 
conformation when bound to the enzyme.[17a] 
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Figure 1. Kifunensine is a potent inhibitor of Caulobacter sp. K31 (CkGH47) D-
mannosidase and binds in a 1C4 conformation. a) Thermodynamics of binding 
between CkGH47 and kifunensine obtained by ITC. The raw data are shown 
in the injection profile (upper panel) and the titration curve (bottom panel). The 
stoichiometry, n, is 0.98 ± 0.01 sites. The association constant, KA, is (2.6 ± 
1.1) x 107 M-1. The enthalpy change, ǻ+, is 19.8 ± 0.3 kcal mol-1. b) Complex 
with kifunensine showing catalytic residues, the Ca2+ ion, and the nucleophilic 
water molecule. Electron density map is REFMAC maximum-likelihood/VA-
weighted 2Fo ± Fc synthesis contoured at 0.80 electrons per Å3, respectively.  
The conformational bias of kifunensine towards the 
southern hemisphere is unusual for a glycosidase inhibitor. For 
example, FELs of the azasugar isofagomine reveal this molecule 
favours a 'normal' 4C1 conformation,[20b] which is also expected 
for the iminosugar deoxymannojirimycin 4. A range of 
iminosugars containing sp2-hybridized atoms, best illustrated by 
mannoimidazole 5, favor half-chair (4H3) and boat (B2,5) 
conformations that lie along the FEL equator.[20] One unusual 
example worth mentioning that is similar to that observed here is 
a mannopyranosiduronic iminosugar, which under acidic 
conditions favors a 1C4 chair, as shown by 1H NMR analysis of 
vicinal coupling constants; however, the presence of the 
carboxylate group prevented binding to D-mannosidases.[6] 
 
Figure 2. Mercator projections of conformational free energy landscapes 
(FELs) of kifunensine and methyl D-mannopyranoside obtained by ab initio 
metadynamics simulations. (Top) FEL for kifunensine in vacuo. The indicated 
observed kifunensine conformations, shown in numbered circles, are for the 
following D-mannosidases: X H. sapiens GH47 (PDB 1FO3), Y B. 
thetaiotaomicron GH92 (PDB 2WVZ), Z D. melanogaster GH38 (PDB 1PS3), 
[ Caulobacter sp. CkGH47 (this work) and \ the small molecule crystal 
structures of kifunensine (KASNOH/KASNOH10). Z, [, and \ adopt almost 
identical conformations, the apparent differences reflect distortions nearing the 
poles of a Mercator projection (see SI Figure S1 for an alternative Polar 
projection). (Bottom) FEL for methyl D-mannopyranoside bound to CkGH47 
from Ref.[17a] Contour lines are separated by 1 kcal/mol.  
 While kifunensine typically binds with nanomolar 
dissociation constants to GH47 D-mannosidases, it is usually a 
far poorer binder/inhibitor for GH families other than family 47. 
The available evidence suggests that all other exo-
mannosidases operate through OS2 l [B2,5]Á l 1S5 
conformational pathways [GH families 2 (retaining),[5b] 38 
(retaining),[22] 92 (inverting)[23] and 125 (inverting)[24]]. Data are 
available for kifunensine binding to representatives of families 38 
and 92. For the Drosophila melanogaster Golgi class II GH38 
retaining D-mannosidase dGMII, 1 has a KI value of 5 mM,[25] 
and it is reported to be a very poor inhibitor of jack bean GH38 
D-mannosidase.[8, 12a] Similarly, for a range of Bacteroides 
thetaiotaomicron inverting GH92 D-mannosidases, 1 is reported 
to have KI values in the range of 100-200 PM.[23] In both cases 
structures of 1 bound to GH38 (PDB 1PS3) and GH92 (PDB 
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2WVZ)[23] D-mannosidases revealed a 1,4B conformation. 
Consideration of these results in the context of the kifunensine 
FEL reveals that while this conformation lies in the energetically 
accessible equatorial region (Figure 2, top), this conformation 
lies some distance away from the OS2 l [B2,5]Á l 1S5 
conformational pathway proposed for both GH38 and 92 D-
mannosidases, suggesting that the poor inhibition results from 
an inability of the inhibitor to adopt a conformation that matches 
species formed on the enzyme during catalysis. 
 Our conformational analysis of kifunensine 1 highlights the 
unique nature of this compound to target a region of the FEL 
that is poorly populated by other GH inhibitors. We suggest that 
the specificity and potency of 1 for family GH47 enzymes is a 
direct consequence of its strong preference for the southern 
hemisphere 1C4 conformation, which matches that of the product 
state of the 3S1 o [3H4]Á o 1C4 conformational itinerary that this 
family of enzymes is believed to utilize.[2b, 16-17] We highlight that 
this analysis suggests that potency is achieved in the absence of 
transition state mimicry. It is surprising that this conformational 
restraint is achieved by introduction of an oxalamide bridge 
without interfering with binding in the active site, as a previous 
attempt to synthetically introduce a bridge into an iminosugar 
with a similar goal failed owing to steric clashes in the active 
site.[5] The conformational preference of kifunensine for a 1C4 
conformation likely arises not merely from the fusion of the 
bridge to the ring, but also from the sp2-hybridization of the 
endocyclic nitrogen as part of an amide. Further, it is noteworthy 
that kifunensine is a neutral species, showing that unlike most 
aza/iminosugar glycosidase inhibitors, kifunensine achieves its 
potency through shape, rather than charge (for a discussion of 
shape versus charge mimicry for the inhibition of a GH99 D-
mannosidase see Ref.[18]; for an example of a potent class of 
neutral GH inhibitors see Ref.[26]). 
In conclusion, this work highlights the capacity of natural 
products to provide inspiration for achieving the goal of selective 
inhibition of glycosidases based on mechanistic principles. 
Aligned with this goal, we highlight the inspiration provided by 
the natural product nagstatin 6,[27] which informed the 
development of the concept of lateral protonation by GHs with a 
catalytic acid or acid/base located anti to the C1-O5 bond, and 
the design of the glycoimidazole class inhibitors that are 
selective for anti-protonating GHs.[28] The existence of 
kifunensine as a GH47 selective inhibitor should inspire 
continuing efforts to develop selective and potent GH inhibitors 
based on targeting unique conformational features of their 
catalysis reaction coordinates. We highlight that one other 
mannosidase family operates through a reversed 1C4 o [3H4]Á o 
3S1 conformational itinerary, namely GH family 134 E-
mannanases.[29] Based on the analysis presented herein, this 
family is likely to be specifically targeted by substrate-mimicking 
kifunensine-derived oligosaccharides relative to the E-
mannanases of GH26 and 113, which operate through OS2 l 
[B2,5]Á l 1S5 conformational pathways.[20b]  
Experimental Section 
CkGH47 protein was cloned, expressed and purified as described 
previously.[17a] The crystallisation conditions were the same as discussed 
in Ref.[6] Mature crystals were soaked in 1 mM kifunensine for 15 hours. 
Data were collected on the Diamond I04-1 MX beamline. After data 
collection, the diffraction images were integrated using xia2[30] and 
reintegrated using AIMLESS from the CCP4 software suite.[31] The Free 
R flag data set was copied from 4AYO. Refinement of the model was 
conducted using multiple rounds of REFMAC and manual model building 
in COOT.[32] Waters were added in using FIND WATERS in COOT and 
validated. The conformation of the ligand was validated using 
PRIVATEER. Coordinates have been deposited on PDB with accession 
code 5NE5; details of refinement quality are shown in Table1 and the 
PDB header. Figures of the structure were produced using CCP4mg.[33] 
ITC was performed using a MicroCal ITC200 calorimeter at 25 °C with 20 
injections. CkGH47 and DMJ were transferred into matching buffer by 
dialysis into 25 mM HEPES pH 7.0, 50 mM NaCl and 2 mM CaCl2. The 
CkGH47 concentration in the cell was 50 µM and the ligand 
concentration was 500 µM. The binding affinity was calculated using the 
Origin7 software. 
The free energy landscape of kifunensine was obtained by density 
functional theory-based metadynamics,[19] using the Car-Parrinello (CP) 
method.[34] The molecule was enclosed in an isolated cubic box of 14.0 Å 
× 14.0 Å × 14.0 Å. A fictitious electron mass of 700 au and a time step of 
0.12 fs ensured a proper conservation of the total energy during the 
simulation. The Kohn-Sham orbitals were expanded in a plane wave 
(PW) basis set with a kinetic energy cutoff of 70 Ry. Ab initio 
pseudopotentials, generated within the Troullier-Martins scheme,[35] were 
employed. The Perdew, Burke and Ernzerhoff generalized gradient-
corrected approximation (PBE)[36] was selected in view of its good 
performance in our previous works.[37] Two collective variables of the 
SXFNHULQJ FRRUGLQDWHV RI &UHPHU DQG 3RSOH ș DQG ĳ ZHUH XVHG WR
explore the conformational space.[38] Initially, the height/width of these 
Gaussian terms was set at 0.6 kcal·mol-1 / 0.10 Å and a new Gaussian-
like potential was added every 250 MD steps. Once the whole free 
energy space was explored, the height of the Gaussian terms was 
reduced to half of its initial value (0.3 kcal·mol-1) and a new Gaussian-like 
potential was added every 500 MD steps. The simulation was stopped 
when energy differences among wells remained constant, which was 
further confirmed by a time-independent free energy estimator.[39] The 
phase space was fully explored in less than 50 ps and the simulation was 
further extended up to 95 ps. The error in the energy difference of the 
principal minima, taken as a standard deviation (SD) from the last 30 ps, 
is below 0.6 kcal mol-1. 
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Perfect fit: Kifunensine is an iminosugar inhibitor with high selectivity for D-
mannosidases of glycoside hydrolase family 47. The free energy landscape for 
kifunensine reveals a strong preference for an inverted 1C4 chair that matches its 
conformation when bound to GH47 enzymes and predicted for the enzyme-product 
state. The selectivity of kifunensine for GH47 D-mannosidases derives from its 
ability to mimic a conformation of the reaction coordinate for GH47 that is distinct 
from that for D-mannosidases of other families. 
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